Aviva plc (OTCMKTS:AVVIY – Get Free Report) was the target of a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 48,600 shares, a growth of 230.6% from the December 31st total of 14,700 shares. Based on an average trading volume of 70,900 shares, the short-interest ratio is presently 0.7 days.
Aviva Stock Performance
AVVIY stock traded up $0.04 during midday trading on Thursday, hitting $12.83. The company had a trading volume of 11,176 shares, compared to its average volume of 31,200. Aviva has a 52 week low of $10.50 and a 52 week high of $13.58. The stock’s 50 day moving average price is $12.17 and its 200 day moving average price is $12.56.
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on AVVIY. Hsbc Global Res upgraded Aviva from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 15th. Royal Bank of Canada raised Aviva to a “moderate buy” rating in a report on Thursday, October 3rd. BNP Paribas upgraded Aviva from a “strong sell” rating to a “hold” rating in a research report on Thursday, December 5th. Finally, Keefe, Bruyette & Woods upgraded Aviva from a “hold” rating to a “moderate buy” rating in a research report on Wednesday, November 27th. One research analyst has rated the stock with a hold rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy”.
Aviva Company Profile
Aviva plc provides various insurance, retirement, investment, and savings products in the United Kingdom, Ireland, Canada, and internationally. The company offers life insurance, long-term health and accident insurance, savings, pension, and annuity products, as well as pension fund business and lifetime mortgage products.
Read More
- Five stocks we like better than Aviva
- Basic Materials Stocks Investing
- How Value Investors Find Undervalued Stocks and Build Wealth
- Stock Market Upgrades: What Are They?
- Is Tonix Pharmaceuticals the Next Biotech Breakout?
- How to Use the MarketBeat Stock Screener
- DeepSeek Dip: Is the Nuclear Energy Sell-Off a Buying Opportunity
Receive News & Ratings for Aviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aviva and related companies with MarketBeat.com's FREE daily email newsletter.